Ra Capital Management, L.P. Myovant Sciences Ltd. Transaction History

Ra Capital Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$4.2 - $19.21 $25.9 Million - $118 Million	-6,166,875 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$5.19 - $9.46 $1.97 Million - $3.58 Million	-378,767 Reduced 5.79%	6,166,875 $32.1 Million
Q2 2019 Aug 14, 2019	BUY	$8.69 - $25.0 $26.1 Million - $75 Million	3,001,415 Added 84.68%	6,545,642 $59.2 Million
Q1 2019 May 15, 2019	SELL	$16.83 - $24.45 $2.82 Million - $4.09 Million	-167,322 Reduced 4.51%	3,544,227 $84.6 Million
Q4 2018 Feb 14, 2019	BUY	$15.01 - $25.2 $3.9 Million - $6.54 Million	259,690 Added 7.52%	3,711,549 $60.9 Million
Q3 2018 Nov 14, 2018	BUY	$19.33 - $26.78 $12 Million - $16.6 Million	621,404 Added 21.95%	3,451,859 $91.6 Million
Q3 2017 Nov 14, 2017	BUY	$9.93 - $15.47 $28.1 Million - $43.8 Million	2,830,455	2,830,455 $43.8 Million

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Ra Capital Management, L.P. with notifications on news.